sergliflozin

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2016
012320072016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
1. Several sodium-glucose cotransporter-2 (SGLT-2) inhibitors are in clinical use for the management of type 2 diabetes. The… (More)
Is this relevant?
2016
2016
Poor pharmacokinetic stability is one of the issues of O-glucoside SGLT2 inhibitors in clinical trials, hence C-glucoside… (More)
Is this relevant?
2012
2012
C-Aryl 5a-carba-β-d-glucopyranose derivatives were synthesized and evaluated for inhibition activity against hSGLT1 and hSGLT2… (More)
Is this relevant?
2010
2010
Sergliflozin, the active entity of sergliflozin etabonate, is a selective inhibitor of sodium-dependent glucose cotransporter 2… (More)
Is this relevant?
2010
2010
Sergliflozin, the active entity of sergliflozin etabonate, is a selective inhibitor of the sodium-dependent glucose cotransporter… (More)
  • figure 1
  • table I
  • table II
  • figure 2
  • table III
Is this relevant?
2009
2009
Sergliflozin etabonate, a novel oral selective low-affinity sodium glucose cotransporter (SGLT2) inhibitor, improves… (More)
Is this relevant?
2009
2009
The low-affinity sodium glucose cotransporter (SGLT2) is responsible for most of the glucose reabsorption in the kidney and has… (More)
Is this relevant?
Review
2009
Review
2009
The kidneys play a major role in the regulation of glucose in humans, reabsorbing 99% of the plasma glucose that filters through… (More)
Is this relevant?
2008
2008
The kidney contains two Na(+)/glucose cotransporters, called SGLT2 and SGLT1, arranged in series along the length of the proximal… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
The low-affinity sodium glucose cotransporter (SGLT2), which is expressed specifically in the kidney, plays a major role in renal… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?